Minerva Neurosciences Inc (NERV : NASDAQ)
Common Stock
$3.48
USD
+0.00 (%)
Last updated: 2026-09-17
Get NERV alerts:
NERV
Minerva Neurosciences Inc
WealthAwesomePerformance
1 Day
-9.01%
1 Week
-15.41%
1 Month
-21.15%
YTD
-16.83%
Key Statistics
Market Cap
$166.40M
52W High
$8.80
52W Low
$2.00
P/E Ratio
-
50 Day MA
$4.41
200 Day MA
$5.08
Beta
-0.10
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/17/2026 | $3.56 | $3.63 | $3.44 | $3.46 | $3.46 | 229,106 |
| 9/16/2026 | $3.83 | $3.88 | $3.48 | $3.48 | $3.48 | 224,376 |
| 9/15/2026 | $4.01 | $4.05 | $3.57 | $3.83 | $3.83 | 287,173 |
| 9/14/2026 | $4.30 | $4.38 | $3.98 | $4.01 | $4.01 | 119,437 |
| 9/11/2026 | $4.24 | $4.38 | $4.13 | $4.15 | $4.15 | 135,947 |
| 9/10/2026 | $4.10 | $4.24 | $4.10 | $4.16 | $4.16 | 72,100 |
| 9/9/2026 | $4.35 | $4.43 | $4.10 | $4.12 | $4.12 | 112,100 |
| 9/8/2026 | $4.40 | $4.46 | $4.32 | $4.37 | $4.37 | 91,800 |
| 9/4/2026 | $4.66 | $4.80 | $4.42 | $4.43 | $4.43 | 78,400 |
| 9/3/2026 | $4.53 | $4.72 | $4.39 | $4.69 | $4.69 | 151,100 |
Analyst Price Targets
Based on 1 analyst covering NERV · as of Sep 17, 2026
Wall Street analysts forecast NERV stock price to rise 196.5% over the next 12 months.
Consensus
Hold3.00 / 5.00
Avg. Target
US$10.33
+196.5% Upside
Current Price
US$3.48
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NERV's historical volatility
30-Day Vol
88.3%
Annualized
90-Day Vol
91.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$2.89
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$3.26 | US$2.40 – US$4.42 |
| 60 trading days | US$3.07 | US$2.00 – US$4.73 |
| 90 trading days | US$2.89 | US$1.71 – US$4.91 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-28.53M
- Profit Margin
- 0.00%
- ROE (TTM)
- -675.09%
- EPS (Diluted)
- -36.12
- Book Value
- -4.52
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About NERV.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DLXY | Delixy Holdings Limited Ordinary Shares | $2.29 | +451.81% |
| MEDS | DataMEDS AI, Inc. | $6.07 | +274.69% |
| SNYR | Synergy CHC Corp. Common Stock | $0.27 | +234.15% |
| QCLS | Q/C Technologies, Inc. | $0.96 | +118.45% |
| AEHL | Antelope Enterprise Holdings Ltd | $9.22 | +78.68% |
| ZTG | Zenta Group Company Limited | $1.18 | +75.33% |
| PDSB | PDS Biotechnology Corp | $0.99 | +69.25% |
| TPST | Tempest Therapeutics Inc | $1.21 | +60.18% |